News

A new peer reviewed report in the journal Molecular Oncology confirms the synergistic effects of the Aminex Therapeutics drug AMXT 1501 combined with DFMO in disrupting the polyamine pathway in Neuroblastoma. Neuroblastoma is a type of cancer affecting nerve cells, primarily afflicts children under the age of 5, and is highly dependent on polyamines to grow and multiply. When DFMO disrupts polyamine biosynthesis in neuroblastoma cells, these cells compensate by increasing their uptake of polyamines from the bloodstream. This article describes how AMXT 1501 inhibits this polyamine uptake and diminishes neuroblastoma cell growth.

Download the Neuroblastoma Article

The International Journal of Cancer has published a peer reviewed study showing the positive impacts of the Aminex drug AMXT 1501 combined with DFMO in targeting acute leukemia. A pre-clinical study sponsored by the Children’s Cancer Institute in Sydney, Australia showed that the combination of these two drugs synergistically inhibit the growth of acute leukemia cell lines by inducing apoptosis (cancer cell death), even when treatment was initiated at high disease burden. The study supports further preclinical and clinical investigation into this treatment approach for acute leukemia.

Download the Leukemia Article

Read More